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(3) P.7: The circulating endothelial damage markers such as 6-keto-PGF1, von Willebrand factors, and thrombomodulin (CD141), and the inflammatory cytokines including IL-17, TNF-, IL-1, IL-8, and IL-6 should be added in text. (4) Usually, the Raynaud's phenomenon is the early clinical manifestation of structural damage or functional derangement of nail-fold capillaries as found in systemic autoimmune diseases such as systemic sclerosis, SLE, and MCTD. Psoriatic diseases seem rarely to manifest Raynaud's phenomenon. The authors should explain what is the hypothesis to conduct the present study.
REVIEWER
Husein Husein-ElAhmed Hospital de Baza, Department of Dermatology, Avda Murcia s/n, Baza, Granada, Spain REVIEW RETURNED 24-Jan-2018
GENERAL COMMENTS
This is very raw study protocol in which is quite difficult to draw any conclusion since authors onlye reflect the material & method planned to be executed in the upcoming months. Although BMJ Open publishes study protocols, those are focused for phase I trials, which does not match with the manuscript submitted by the authors.
Regarding the text provided by the authors, 25 healthy controls seem a very short quantity to me. Case-control study usually have a ratio 1:2, although in certain situations a ratio 1:1 can be accepted. I suggest authors to equalize the quantity of cases and controls so that the power of the study is increased and any drawn conclusion will be more relevant.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1:
1. "Only the protocol has been described in this manuscript, but this manuscript does not contain results. Please, it may be worthwhile to wait to publish until the authors have actually evaluated patients and can display results?"
• The submitted manuscript intentionally and solely represents a study protocol. The publication of the study protocol prior to a clinical trial has become a prerequisite for many highly ranked medical journals. Publishing study protocols enables researchers and funding bodies to stay up-to-date in their fields by providing exposure to research activities that may otherwise not be widely publicized. This can help prevent unnecessary duplications of work and will hopefully enable collaborations. Publishing protocols in full also makes available more information than is currently required by trial registries and increases transparency, making it easier for others (editors, reviewers and readers) to see and understand details, e.g. the sample-size calculation, the statistical evaluation plan, and any deviations from the protocol that potentially occurred during the conduct of the study. The final results will be published as an original study once the study has been successfully completed.
2. "The authors may update the terminology used in the methodology with curent international consensus standardisation efforts: in this way morphology can be categorised in "normal" (tortuous, crossing, hairpin shaped) and not normal.
(Rheumatology (Oxford). 2016 May;55(5):883-90. doi: 10.1093/rheumatology/kev441; Ramification would be categorised as "abnormal" shape."
• Thank you for this helpful suggestion. In the manuscript "An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases" by Smith et al. simple capillaroscopic definitions for interpretation of capillaroscopic morphologies are described which were considered in the revised text.
3. Reviewer 2:
1. "The title of the manuscript seems not appropriate because the authors try to compare psoriasis vulgaris and psoriatic arthritis both disease entities can be combined as "psoriatic disease". Accordingly, "psoriasis vulgaris" should be changed to "psoriatic disease".
• Within this study we are focused on capillary pathologies in patients with psoriasis vulgaris. Therefore, we compare patients suffering from psoriasis vulgaris with healthy controls. A second group of patient suffering from psoriasis vulgaris in combination with accompanying psoriasis arthritis will be evaluated to identify a possible influence of the joint involvement. Subjects with non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular) will be excluded from this study. Therefore, the term "psoriatic disease" could be misunderstood and we prefer not to revise the title of the manuscript.
2. "Hyperuricemia is a common co-morbidity in psoriatic disease. The authors have to add in text. The hyperglycemia and hyperlipidemia may probably secondary derive from obesity. The cause-effect relationships should be clarified."
• All accompanying medical conditions (incl. co-morbidities such as hyperuricemia) are not mentioned explicitly in the manuscript owing to space constraints. However, they will be prospectively assessed within this study.
3. "P.7: The circulating endothelial damage markers such as 6-keto-PGF1a, von Willebrand factors, and thrombomodulin (CD141), and the inflammatory cytokines including IL-17, TNF-a, IL-1b, IL-8, and IL-6 should be added in text."
• Within this clinical study circulating markers of endothelial damage and inflammation, such as von Willebrand factor, fibrinogen, D-dimer, erythrocyte sedimentation rate (ESR) will be analyzed in our inhouse laboratory as part of the routine blood testing. More specialized analyses, such as measuring of certain cytokine-levels will unfortunately not be possible within our routine blood testing. Since this study will focus on capillary pathologies in patients with psoriasis vulgaris and this evaluation is only a secondary objective we unfortunately have to refrain from a more extensive laboratory workup.
4. "Usually, the Raynaud's phenomenon is the early clinical manifestation of structural damage or functional derangement of nail-fold capillaries as found in systemic autoimmune diseases such as systemic sclerosis, SLE, and MCTD. Psoriatic diseases seem rarely to manifest Raynaud's phenomenon. The authors should explain what is the hypothesis to conduct the present study."
• This study does not asses Raynaud's phenomenon at all, but will focus on pathological changes in nailfold capillaries of psoriasis patients. To date, reports on morphological changes of the non-lesional nailfold capillaries in patients with psoriasis vulgaris are scarce and the existing data is not conclusive. We hypothesize that early endothelial dysfunction, which plays a crucial role in the pathogenesis of atherosclerosis, may be detected by digital video nailfold capillaroscopy at the level of the dermal capillary microvasculature as a surrogate parameter. Psoriatic disease is not associated with Raynaud's phenomenon and will not be assessed within this study.
4. Reviewer 3:
1. "This is very raw study protocol in which is quite difficult to draw any conclusion since authors onlye reflect the material & method planned to be executed in the upcoming months. Although BMJ Open publishes study protocols, those are focused for phase I trials, which does not match with the manuscript submitted by the authors."
• The submitted manuscript intentionally and solely represents a study protocol. As described above, the publication of study protocols prior to the start of a prospective study has become a prerequisite for many highly ranked medical journals. BMJ Open allows for the publication of study protocols of all phases. Protocol manuscripts should report planned or ongoing research studies.
2. "Regarding the text provided by the authors, 25 healthy controls seem a very short quantity to me. Case-control study usually have a ratio 1:2, although in certain situations a ratio 1:1 can be accepted. I suggest authors to equalize the quantity of cases and controls so that the power of the study is increased and any drawn conclusion will be more relevant."
• As this is a first pilot study investigating the frequency and extent of capillary pathologies in patients with psoriasis vulgaris, a formal sample size calculation could not be performed. A sample size of 75 completed and evaluable datasets was chosen for reasons of feasibility. This pilot study plays an important role in providing information for the planning and justification of a study in a larger patient cohort also including more healthy controls.
VERSION 2 -REVIEW

REVIEWER
Husein Husein-ElAhmed Department of Dermatology. Hospital de Baza, Granada, Spain REVIEW RETURNED 15-Mar-2018
GENERAL COMMENTS
As I stated previously, this protocol proposes an interesting topic to be focused, but it just that: A protocol. Since, BMJ Open accepts protocols, this may be considered, but only after all the issues regarding any protocol have been addressed and the authors' protocols lacks on the sample size. Authors have stated: "A sample size of 75 complete and evaluable datasets is sufficient to assess the potential impact of psoriasis on capillary pathologies by descriptive statistics" What's the basis to state that? I think this should be deleted from the text unless suported by references, and clear calculation of the sample size should be performed.
VERSION 2 -AUTHOR RESPONSE
Reviewers' Comments to the Authors: Comments from the Statistical Advisory Board:
I have looked through the manuscript with the aim of providing a statistical review. 1) I note in the authors favour that the protocol has been approved by the independent ethics committee of the medical faculty of the University of Heidelberg.
2) The authors state that they will have 50 patients with psoriasis vulgaris alone or psoriasis vulgaris accompanied by psoriasis arthritis, and will compare the results to 25 healthy subjects. However, I did not see a justification provided for the selecting only 25 healthy subjects. I would expect the authors to at least sample the same number of controls as cases, as Reviewer 3 has pointed out. The response by the authors has not addressed this specific question.
• As suggested, we increased the number of healthy subjects from 25 to 50. In total, we will evaluate 100 patients. We changed the number of patients that shall be recruited throughout the manuscript.
3) Since the authors say that this is a first pilot study and a sample size is neither feasible nor applicable, I would like to put to the authors if in their protocol they can state that the proposed study will be a pilot study to determine the feasibility of a fully powered RCT, and to clarify the sample size calculation needed.
• As requested, we added a specific justification for the sample size in the "Statistical considerations" section. Furthermore, we provided a statement as to why this is an exploratory study in the introduction and methods section for further clarification.
Reviewer: 3 As I stated previously, this protocol proposes an interesting topic to be focused, but it just that: A protocol. Since, BMJ Open accepts protocols, this may be considered, but only after all the issues regarding any protocol have been addressed and the authors' protocols lacks on the sample size. Authors have stated: "A sample size of 75 complete and evaluable datasets is sufficient to assess the potential impact of psoriasis on capillary pathologies by descriptive statistics" What's the basis to state that? I think this should be deleted from the text unless supported by references, and clear calculation of the sample size should be performed.
• As stated above, we sought professional advice from a biometrician of the Institute of Medical Biometry and Informatics of the University of Heidelberg for the required statistical adjustments and added a specific justification for the sample size in the "Statistical considerations" section. Additionally, we increased the number of healthy subjects from 25 to 50 and changed the number of patients that shall be recruited throughout the manuscript.
VERSION 3 -REVIEW REVIEWER
Husein Husein-ElAhmed Department of Dermatology, Hospital de Baza, Granada, Spain REVIEW RETURNED 21-May-2018
GENERAL COMMENTS
Manuscript has improved but I still find two issues to be addressed regarding the Healthy control group: In text, it states that 50 subjects will be included within this group, although in the Figure 1 , only 32 have been included. Please clarify. Besides, authors have included abscence of autoimmune diseases as one inclusion criteria in the control group, but they should have included abscence of cardiovascular diseases too. It should be added in the text. The overall protocol has been polished greatly, although it remains too vague for me: Maybe those outcomes related to serum cardiovascular risks such as erythrocyte sedimentation rate or creactive protein should be addressed as authors did in Table 1 .
VERSION 3 -AUTHOR RESPONSE
Reviewer: 3:
Manuscript has improved but I still find two issues to be addressed regarding the Healthy control group: In text, it states that 50 subjects will be included within this group, although in the Figure 1 , only 32 have been included. Please clarify.
• Thank you for pointing this out to us. When we increased the number of healthy subjects from 25 to 50 we unfortunately missed to adjust the figure. We have now also revised the number of required healthy subjects in Figure 1 .
Besides, authors have included abscence of autoimmune diseases as one inclusion criteria in the control group, but they should have included abscence of cardiovascular diseases too. It should be added in the text.
• As suggested, we added the abscence of cardiovascular diseases as an exclusion criterion in the control group.
The overall protocol has been polished greatly, although it remains too vague for me: Maybe those outcomes related to serum cardiovascular risks such as erythrocyte sedimentation rate or c-reactive protein should be addressed as authors did in Table 1 .
• As requested, we specifically addressed the circulating markers of endothelial damage and inflammation by adding an additional table 2 in the manuscript.
